Histone Deacetylase Inhibitors - Epidrugs for Neurological Disorders (inbunden)
Inbunden (Hardback)
Antal sidor
1st ed. 2019
Springer Verlag, Singapore
93P8 illus 20 Tables, color 5 Illustrations, color 3 Illustrations, black and white XVII 5
20 Tables, color; 5 Illustrations, color; 3 Illustrations, black and white; XVII, 93 p. 8 illus., 5
239 x 168 x 10 mm
309 g
Antal komponenter
1 Hardback
Histone Deacetylase Inhibitors - Epidrugs for Neurological Disorders (inbunden)

Histone Deacetylase Inhibitors - Epidrugs for Neurological Disorders

Inbunden Engelska, 2019-07-15
Skickas inom 7-10 vardagar.
Fri frakt inom Sverige för privatpersoner.
Finns även som
Visa alla 2 format & utgåvor
This book provides an outline of epigenetics as a whole, while also specifically examining a range of epigenetic players, including histone acetyl transferases (HATs) and histone deacetylases (HDACs). It chiefly focuses on the emerging targets of HDACs and their implications for various neurological disorders, while also discussing the drawbacks of current therapeutic strategies, the classification of HDAC inhibitors, and their promising effects in connection with specific neurological disorders. The book explores the potential use of these inhibitors as novel therapeutic agents, considers the current challenges involved in using them to tackle neurological complications, and offers a novel solution by designing isoform-selective inhibitors and employing combinatorial therapeutic strategies. Its final section, which explores future directions, elaborates on the possibility of enhancing HDAC inhibitors' therapeutic efficacy against various neurological complications.
Visa hela texten

Passar bra ihop

  1. Histone Deacetylase Inhibitors - Epidrugs for Neurological Disorders
  2. +
  3. Histone Deacetylases: the Biology and Clinical Implication

De som köpt den här boken har ofta också köpt Histone Deacetylases: the Biology and Clinical ... av Tso-Pang Yao, Edward Seto (inbunden).

Köp båda 2 för 4918 kr


Har du läst boken? Sätt ditt betyg »

Bloggat om Histone Deacetylase Inhibitors - Epidrugs...

Övrig information

Dr. Shabir Ahmad Ganai is currently working as Assistant Professor Cum Junior Scientist, Division of Basic Sciences and Humanities, Faculty of Agriculture, SKUAST-Kashmir, Wadura, Sopore, 193201, Jammu & Kashmir, India. He has done his masters in Biochemistry from Bangalore University (2005-2007) and earned his Ph.D. from elite SASTRA University (2009-2014). Later, he did his post-doctorate from National Brain Research Centre, Haryana, India. He has also served as research fellow in SKUAST-Kashmir. His research interests are focused on understanding the modulations of the nuclear geometry and post-translational modifications during treatment with structurally distinct HDAC inhibitors. He has been actively involved in designing the target-selective inhibitors against Class II HDACs using various bioinformatics tools. Dr. Shabir Ahmad Ganai has published more than 20 research articles and one editorial in high impact factor international Journals. He has also served as guest editor for a thematic issue (Epigenetics: A novel frontier for drug discovery) published by Current Medicinal Chemistry. In addition, he serves as a referee for many reputed international journals like Current Drug Targets, PLOS ONE and Medicinal Chemistry Research. He is an active member of many national and international societies including, The International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT).


Chapter 1. Role of Epigenetics in neurological diseases.- Chapter 2. Epigenetic enzymes and the drawbacks of conventional therapeutic regimens.- Chapter 3. Distinct classes of HDACs.- Chapter 4. HDAC implications in neurological diseases.- Chapter 5. HDAC inhibitors and their structurally distinct groups.- Chapter 6. HDAC inhibitors as novel therapeutic option against therapeutically challenging neurological disorders.- Chapter 7. Current Challenges with HDAC inhibitor based therapeutic intervention against neurological maladies.- Chapter 8. Escalating need of isoform selective inhibitors for enhanced therapeutic efficacy.- Chapter 9. Combinatorial therapeutic regimens using HDAC inhibitors in conjunction with conventional therapeutic agents.- Chapter 10. Future directions of epigenetic research in tackling neurological complications.